SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Contemporary art collage of woman sitting in the lotus position, cloud, pillows against the background of the night sky. Concept of healthy lifestyle and sport. Good and relaxing sleep. Copy space.
Mergers & acquisitions
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
A day after Pfizer closed its hotly contested Metsera deal, Lundbeck has made an unsolicited offer to steal Avadel Pharmaceuticals away from Alkermes.
November 14, 2025
 · 
1 min read
 · 
Annalee Armstrong
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Mergers & acquisitions
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
At $9.2 billion, the Cidara acquisition lands among the top 5 largest deals of the year.
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV who are on complex treatment regimens, according to BMO Capital Markets.
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Different business strategies. Various solutions. Splitting opinions. Choosing way. Movement options. Separation of directions. Dilemma concept. Two diverging paths of arrows. 3d render
Vaccines
Pfizer Reportedly Planning To Divest BioNTech Stake
A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration.”
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Opinion
How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
November 14, 2025
 · 
6 min read
 · 
Anshul Mangal
Shanghai.China-Feb.25th 2022: Pfizer company sign on office building. Pharmaceutical and biotechnology corporation
Mergers & acquisitions
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the market in 2028.
November 13, 2025
 · 
1 min read
 · 
Annalee Armstrong
Paper red boat sailing in the ocean or sea, travel concept. Blue sea waves layers. Modern paper art style 3d render
Editorial
FDA’s Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water
Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts agree, needs to take control of the narrative.
November 13, 2025
 · 
8 min read
 · 
Jef Akst
arrow down stock market investment global red technology background. Global economic slowdown and crisis. vector illustration fantastic technology.
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.
November 13, 2025
 · 
3 min read
 · 
Annalee Armstrong
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity.
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS